This module aims to provide an overview of familial hypercholesterolaemia (FH) in Malaysia, major challenges of under-detection and under-treatment of FH and lifetime risk for FH patients.
This Continuous Medical Education (CME) is supported by Amgen Biopharmaceuticals Malaysia Sdn Bhd.
You must be a member to access this content.
To become a member, please register here.
If you're already a member, please sign in to access.